Search Results

You are looking at 31 - 40 of 91 items for :

  • "cytoreduction" x
  • Refine by Access: All x
Clear All
Full access

An Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse

Scott M. Lindhorst, Richard D. Lopez, and Ronald D. Sanders

contained the gene fusion. Based on the high white count presentation, the patient was admitted to an outside hospital where cytoreduction consisting of hydroxyurea and imatinib at 800 mg/d was initiated. Similar major molecular response rates at 1 year

Full access

What’s in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia

Andrew T. Kuykendall and Rami Komrokji

thrombotic and bleeding events. Although these data support the protective benefit of hydroxyurea, especially in patients with platelet control, it is likely that the agent exerts its influence via multiple mechanisms. In addition to providing cytoreduction

Full access

Treatment of Acute Promyelocytic Leukemia for Older Patients

Thomas Prebet and Steven D. Gore

. Complete remission rates for ATO-based induction range from 86% to 94%. Molecular responses after induction range from 76% to 100%. In patients with a high WBC count at diagnosis or after the beginning of treatment, cytoreduction is mandatory to limit the

Full access

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes

cytoreduction, followed in most (but not all) patients by systemic therapy. 90 – 93 Neoadjuvant therapy refers to drugs, radiation, or other treatment that is given to reduce the tumor burden before cancer surgery. The therapeutic benefit of neoadjuvant

Full access

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

MPM. 74 – 79 Surgery For patients with MPM, the goals of surgery may differ depending on the needs of the patient. Surgery will be recommended in select patients with good PS and epithelioid or mixed histology if a complete gross cytoreduction

Full access

New Issues in Systemic Therapy for Ovarian Cancer

Deborah K. Armstrong

overall debulking rate was very low in this population, around 20%,” she added. “Most surgeons hope to have complete cytoreduction in at least half their patients. This indicates that, for patients who do not receive good surgery, neoadjuvant chemotherapy

Full access

Clinical Treatment Decisions for Advanced Renal Cell Cancer

Toni K. Choueiri

acts on the disease biology and slows the progression of disease, Dr. Choueiri said. Cytoreduction Nephrectomy in the Targeted Therapy Era The need to obtain tumor tissue in the era of targeted therapies renders biopsy and/or cytoreductive

Full access

Progressive Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Cell Transplantation

Potjana Jitawatanarat, Arpita Desai, Pradeep Sharda, Hong Liu, Maureen Ross, Francisco J. Hernandez-llizaliturri, Philip L. McCarthy, and George L. Chen

with second-line therapy for relapsed or refractory disease after alloHCT. 5 DHAC was initially given for cytoreduction. 5 Because of reports indicating decreased effects in bulky disease, alemtuzumab was not initially given, although it was started

Full access

Counterpoint: Chemosensitivity Assays for Recurrent Ovarian Cancer

Maurie Markman

of residual disease after primary surgical cytoreduction, and, in the case of advanced disease, morphologic subtype (e.g., mucinous vs. papillary serous). Importantly, however, even if this prognostic information helps patients and physicians make

Full access

New Therapies for Ovarian Cancer

David M. O’Malley

, or fallopian tube cancer . J Clin Oncol 2012 ; 30 : 2039 – 2045 . 22529265 10.1200/JCO.2012.42.0505 6. Coleman RL , Brady MF , Herzog TJ , . Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent